Document is current
Any future updates will be listed below
-
Authors
Madsen, Ralitsa R https://orcid.org/0000-0001-8844-5167
Le Marois, Alix
Mruk, Oliwia N https://orcid.org/0009-0000-6516-3757
Voliotis, Margaritis https://orcid.org/0000-0001-6488-7198
Yin, Shaozhen
Sufi, Jahangir https://orcid.org/0000-0002-4563-5531
Qin, Xiao https://orcid.org/0000-0002-8738-4187
Zhao, Salome J https://orcid.org/0009-0009-3715-0305
Gorczynska, Julia https://orcid.org/0009-0006-6379-1438
Morelli, Daniele https://orcid.org/0000-0002-3714-6658
Davidson, Lindsay
Sahai, Erik
Korolchuk, Viktor I
Tape, Christopher J
Vanhaesebroeck, Bart https://orcid.org/0000-0002-7074-3673
-
Funding
Funding for this research was provided by:
Wellcome Trust (C23338/A25722)
Cancer Research UK (C23338/A25722)
Cancer Research UK (C60693/A23783)
Cancer Research UK City of London Centre (C7893/A26233)
Cancer Research UK core funding (CC2040)
UK Medical Research Council core funding (CC2040)
Wellcome Trust core funding (CC2040)
EC | European Research Council (101019366)
UCL Research Capital Infrastructure
UCLH Biomedical Research Centre (BRC422)
EC | Horizon 2020 Framework Programme (952266)
VitaDAO/Molecule academic partnership
Longaevus Technologies
Lilly Research (28008)
Astra Zeneca
CLOVES Syndrome Community
- License Information
-
More Information
Article History
Received: 21 October 2024
Revised: 6 November 2024
Accepted: 11 November 2024
First Online: 20 December 2024
Disclosure and competing interests statement
: RRM has received consulting fees from Nested Therapeutics (Cambridge, U.S.) and serves on the Scientific Advisory Board of CLOVES Syndrome Community. BV is a consultant for iOnctura (Geneva, Switzerland) and Pharming (Leiden, the Netherlands) and a shareholder of Open Orphan (Dublin, Ireland). ES is a consultant for Phenomic AI (Toronto, Canada) and Theolytics (Oxford, UK), receives research funding from AstraZeneca, MSD and Novartis. VIK is a scientific advisor for Longaevus Technologies. The remaining authors declare no competing interests.
